P Bhargava

Summary

Affiliation: University of Massachusetts Medical School
Country: USA

Publications

  1. ncbi request reprint Hypersensitivity and idiosyncratic reactions to oxaliplatin
    Pankaj Bhargava
    Cancer 100:211-2. 2004
  2. ncbi request reprint Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report
    Pankaj Bhargava
    University of Massachusetts Medical School, UMass Memorial Medical Center, Worcester, Massachusetts, USA
    Oncology (Williston Park) 17:23-6. 2003
  3. ncbi request reprint A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers
    P Bhargava
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Clin Cancer Res 7:3912-9. 2001
  4. ncbi request reprint A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer
    P Bhargava
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Clin Cancer Res 5:1989-95. 1999
  5. ncbi request reprint Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer
    P Bhargava
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Cancer Chemother Pharmacol 48:95-103. 2001
  6. ncbi request reprint Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol
    David Gammon
    UMass Memorial Medical Center, 55 Lake Avenue North, Worcester, Massachusetts 01655, USA
    Oncologist 9:546-9. 2004
  7. ncbi request reprint Transpulmonary CT-guided radiofrequency ablation of liver metastasis
    Sridhar Shankar
    Department of Radiology, University of Massachusetts, Worcester, Massachusetts 01655, USA
    Cardiovasc Intervent Radiol 28:481-4. 2005
  8. ncbi request reprint Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report and review of the literature
    N Bangalore
    Division of Hematology/Oncology, Lombardi Cancer Center, Washington, DC 20007, USA
    Ann Oncol 12:271-4. 2001
  9. ncbi request reprint Phase I study of prolonged infusion Bryostatin-1 in patients with advanced malignancies
    John L Marshall
    Lombardi Cancer Center, Georgetown University Medical Center, Washington DC 20007, USA
    Cancer Biol Ther 1:409-16. 2002
  10. ncbi request reprint Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Cancer 110:581-9. 2007

Detail Information

Publications14

  1. ncbi request reprint Hypersensitivity and idiosyncratic reactions to oxaliplatin
    Pankaj Bhargava
    Cancer 100:211-2. 2004
  2. ncbi request reprint Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report
    Pankaj Bhargava
    University of Massachusetts Medical School, UMass Memorial Medical Center, Worcester, Massachusetts, USA
    Oncology (Williston Park) 17:23-6. 2003
    ..The combination of gemcitabine plus irinotecan appears to possess modest clinical activity, and it is well tolerated in patients with advanced biliary cancer. Patient accrual is ongoing to this study...
  3. ncbi request reprint A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers
    P Bhargava
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Clin Cancer Res 7:3912-9. 2001
    ..v. infusion every two weeks; and (b) to obtain information on prolonged (>120-h) continuous i.v. infusions in patients who have tolerated 120-h infusions...
  4. ncbi request reprint A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer
    P Bhargava
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Clin Cancer Res 5:1989-95. 1999
    ..v over 4 h. The principal DLT was neurotoxicity, which appeared to be dose-related and was completely reversible. On the basis of the short plasma t(1/2) of TNP-470, exploration of a prolonged i.v. infusion schedule is warranted...
  5. ncbi request reprint Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer
    P Bhargava
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Cancer Chemother Pharmacol 48:95-103. 2001
    ..Minimally pretreated patients tolerated higher doses of this combination without significant toxicities. This schedule and combination demonstrated activity in a variety of solid tumors, and merits further evaluation...
  6. ncbi request reprint Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol
    David Gammon
    UMass Memorial Medical Center, 55 Lake Avenue North, Worcester, Massachusetts 01655, USA
    Oncologist 9:546-9. 2004
    ..The desensitization protocol is described in detail...
  7. ncbi request reprint Transpulmonary CT-guided radiofrequency ablation of liver metastasis
    Sridhar Shankar
    Department of Radiology, University of Massachusetts, Worcester, Massachusetts 01655, USA
    Cardiovasc Intervent Radiol 28:481-4. 2005
    ..The percutaneous approach for RF ablation of liver lesions high up in the dome is always difficult. The authors describe a transpulmonary approach that may be simpler and safer to use...
  8. ncbi request reprint Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report and review of the literature
    N Bangalore
    Division of Hematology/Oncology, Lombardi Cancer Center, Washington, DC 20007, USA
    Ann Oncol 12:271-4. 2001
    ..Notably, all responses were seen with doxorubicin containing regimens, suggesting that doxorubicin is a critical component in chemotherapy regimens for SRCC...
  9. ncbi request reprint Phase I study of prolonged infusion Bryostatin-1 in patients with advanced malignancies
    John L Marshall
    Lombardi Cancer Center, Georgetown University Medical Center, Washington DC 20007, USA
    Cancer Biol Ther 1:409-16. 2002
    ..Therefore we performed a phase 1 clinical trial to determine the safety and recommended dose of prolonged infusion Bryostatin-1...
  10. ncbi request reprint Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Cancer 110:581-9. 2007
    ..A phase 2 study was performed with cetuximab, a chimeric monoclonal antibody that binds specifically to EGFR, in patients with advanced HCC...
  11. ncbi request reprint Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
    Vered Stearns
    The Breast Cancer Program, Department of Medicine, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    J Natl Cancer Inst 95:1758-64. 2003
    ..In a prospective clinical trial, we tested the effects of coadministration of tamoxifen and the SSRI paroxetine, an inhibitor of CYP2D6, on tamoxifen metabolism...
  12. ncbi request reprint Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Dig Dis Sci 53:564-70. 2008
    ....
  13. ncbi request reprint Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 24:1898-903. 2006
    ....
  14. ncbi request reprint Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology
    Margaret Tempero
    UCSF Comprehensive Cancer Center
    J Natl Compr Canc Netw 5:998-1033. 2007